… increase in total hip BMD. The change in total hip BMD between Treatment Days 2 and 121
… to placebo for the 3.2 mg GLP-2 group (P = 0.007) and for the 1.6 mg GLP-2 group (P = 0.042…

… to assess the changes of BMD, especially the total hip of BMD. … , GLP-1RAs have an effect
of maintaining BMD and provide a treatment option for patients with osteoporosis and type 2 …

… 2 diabetes, total and hip BMD was unchanged after modest weight loss induced by 1.8 mg of
liraglutide. The GLP-1RA exenatide was associated with increased hip BMD … risk with GLP-…

… Moreover, GLP-2 has been shown to dose-dependently increase BMD after four months of
… long-term GLP-2 treatment. Importantly, significant increases in BMD of total hip, trochanter, …

… treatment significantly and dose dependently increased BMD in postmenopausal women
(29). It is unknown whether GLP-2 also decreases bone resorption in T2D, but the effect may …

… This article describes the effect of GLP-2 on spinal and hip bone mineral density (BMD) and
biochemical markers of bone turnover in these patients. Methods: In an open-labelle d pilot …

… of the incretin hormones glucagon-like peptide 1 (GLP-1), glucagon-like peptide 2 (GLP-2),
and … Osteoblasts and osteoclasts that variably express receptors for GIP, GLP-1, and GLP-2, …

… GLP-2 treatment shows no sign of tachyphylaxis or generation of GLP-2 antibodies [10,11]
and four months of GLP-2 … to increase bone mineral density (BMD measured by DEXA) [11]. …

… with a small reduction in the total BMD at the hip but not at other skeletal sites. However,
the authors noted that the reduced BMD with canagliflozin treatment was unlikely due to its …

… cannot ascertain that GLP-2 is responsible for the abnormal bone remodeling in T2D.
Nevertheless, we found a positive correlation between GLP-2 and femoral neck and total hip BMD, …